

(OFFICE TRANSLATION)

PROTOKOLL FRA ORDINÆR GENERALFORSAMLING**MINUTES OF ANNUAL GENERAL MEETING****I****OF**

OBSERVE MEDICAL ASA
ORGANISASJONSNUMMER 822 907 822

OBSERVE MEDICAL ASA
COMPANY REGISTRATION NUMBER 822 907 822

Den 3. juni 2022 kl. 10.00 ble det avholdt ordinær generalforsamling i Observe Medical ASA ("**Selskapet**") i Haakon VII's gate 2, 0161 Oslo, Norge og som elektronisk møte gjennom Lumi AGM.

The annual general meeting of Observe Medical ASA (the "**Company**") was held on 3 June 2022 at 10:00 hours (CEST) at Haakon VII's gate 2, 0161 Oslo, Norway and as an electronic meeting through Lumi AGM.

Generalforsamlingen ble åpnet av styrets leder, Terje Bakken, som opptok fortegnelse over møtende aksjeeiere og fullmakter. Fortegnelsen, inkludert antall aksjer og stemmer representert, er inntatt som Vedlegg 1 til protokollen.

The general meeting was opened by the chairperson of the board of directors, Terje Bakken, who kept a record of attending shareholders and proxies. The record, including the number of shares and votes represented, is attached to these minutes as Appendix 1.

I henhold til fortegnelsen var 17 628 821 av totalt 53 491 656 utstedte aksjer og stemmer, som tilsvarer 32,96 % av det totale antall stemmeberettigede aksjer i Selskapet, representert på generalforsamlingen.

According to the record, 17,628,821 of a total of 53,491,656 issued shares and votes, corresponding to 32,96% of the total number of voting shares in the Company, were represented at the general meeting.

Til behandling forelå følgende agendapunkter:

The following matters were on the agenda:

1 VALG AV MØTELEDER**1 ELECTION OF A PERSON TO CHAIR THE MEETING**

I samsvar med styrets forslag traff generalforsamlingen følgende vedtak:

In accordance with the board of directors' proposal, the general meeting passed the following resolution:

Terje Bakken velges som møteleder.

Terje Bakken is elected to chair the meeting.

Beslutningen ble truffet med nødvendig flertall, jf. avstemningsresultat inntatt som Vedlegg 2 til protokollen.

The resolution was passed with the required majority, cf. the result of the voting set out in Appendix 2 to the minutes.

2 VALG AV EN PERSON TIL Å MEDUNDERTEGNE PROTOKOLLEN**2 ELECTION OF A PERSON TO CO-SIGN THE MINUTES**

Generalforsamlingen valgte Per Arne Nygård til å medundertegne protokollen sammen med møtelederen.

The general meeting elected Per Arne Nygård to co-sign the minutes together with the chairperson of the meeting.

Beslutningen ble truffet med nødvendig flertall, jf. avstemningsresultat inntatt som Vedlegg 2 til protokollen.

The resolution was passed with the required majority, cf. the result of the voting set out in Appendix 2 to the minutes.

3 GODKJENNING AV INNKALLING OG DAGSORDEN**3 APPROVAL OF THE NOTICE AND THE AGENDA**

Møteleder opplyste om at innkalling og dagsorden til generalforsamlingen hadde blitt sendt til samtlige aksjeeiere

The chairperson of the meeting informed the general meeting that the notice and the agenda had been sent to all shareholders with

med kjent oppholdssted den 13. mai 2022.

I samsvar med styrets forslag traff generalforsamlingen følgende vedtak:

Innkallingen og dagsorden sendt til samtlige aksjeeiere med kjent adresse den 13. mai 2022, godkjennes.

Beslutningen ble truffet med nødvendig flertall, jf. avstemmingsresultat inntatt som Vedlegg 2 til protokollen.

Møtelederen erklærte generalforsamlingen som lovlig satt.

4 ORIENTERING OM SELSKAPETS VIRKSOMHET

Selskapets daglige leder, Rune Nystad, ga en orientering om Selskapets virksomhet.

5 GODKJENNING AV ÅRSREGNSKAP OG ÅRSBERETNING FOR REGNSKAPSÅRET 2021

I samsvar med styrets forslag traff generalforsamlingen følgende vedtak:

Selskapets selskapsregnskap for regnskapsåret 2021 og Selskapets årsrapport, herunder konsernregnskapet og årsberetningen for regnskapsåret 2021, godkjennes.

Beslutningen ble truffet med nødvendig flertall, jf. avstemmingsresultat inntatt som Vedlegg 2 til protokollen.

6 STYREVALG

I samsvar med valgkomiteens innstilling traff generalforsamlingen følgende vedtak:

Eskild Endrerud og Line Tønnessen velges som nye styremedlemmer til Selskapets styre fra valgtidspunktet, og erstatter styremedlem Thomas B. Grünfeld. Endrerud og Tønnessen velges for en periode på ett år, frem til den ordinære generalforsamlingen i 2023.

Etter styrevalget består Selskapets styre av følgende personer:

- Terje Bakken (leder);
- Kathrine Gamborg Andreassen;
- Sanna Rydberg;
- Line Tønnessen; og
- Eskild Endrerud.

known address on 13 May 2022.

In accordance with the board of directors' proposal, the general meeting passed the following resolution:

The notice and the agenda which were sent to all shareholders with a known address on 13 May 2022, are approved.

The resolution was passed with the required majority, cf. the result of the voting set out in Appendix 2 to the minutes.

The chairperson of the meeting declared the general meeting as lawfully convened.

4 INFORMATION ABOUT THE COMPANY'S ACTIVITIES

The Company's CEO, Rune Nystad, gave an account of the Company's activities.

5 APPROVAL OF THE ANNUAL ACCOUNTS AND THE ANNUAL REPORT FOR THE FINANCIAL YEAR 2021

In accordance with the board of directors' proposal, the general meeting passed the following resolution:

The Company's annual accounts for the financial year 2021 and the Company's annual report, including the group's annual accounts and the board of directors' report for the financial year 2021, are approved.

The resolution was passed with the required majority, cf. the result of the voting set out in Appendix 2 to the minutes.

6 BOARD ELECTION

In accordance with the nomination committee's proposal, the general meeting passed the following resolution:

Eskild Endrerud and Line Tønnessen are elected as new members of the Company's board of directors from the time of the election, and replaces board member Thomas B. Grünfeld. Endrerud and Tønnessen are elected for a one-year-term, until the annual general meeting in 2023.

Following the board election, the Company's board of directors comprises the following persons:

- Terje Bakken (chair);
- Kathrine Gamborg Andreassen;
- Sanna Rydberg;
- Line Tønnessen; and
- Eskild Endrerud.

Beslutningen ble truffet med nødvendig flertall, jf. avstemmingsresultat inntatt som Vedlegg 2 til protokollen.

The resolution was passed with the required majority, cf. the result of the voting set out in Appendix 2 to the minutes.

7 VALG AV MEDLEMMER TIL VALGKOMITEEN

7 ELECTION OF MEMBERS TO THE NOMINATION COMMITTEE

I samsvar med valgkomiteens innstilling traff generalforsamlingen følgende vedtak:

In accordance with the nomination committee's proposal, the general meeting passed the following resolution:

Bård Brath Ingerø (leder) og Grete Hogstad gjenvelges som medlemmer av valgkomiteen for en periode på ett år, frem til den ordinære generalforsamlingen i 2023.

Bård Brath Ingerø (chair) and Grete Hogstad are re-elected as members of the nomination committee for a one-year term, until the annual general meeting in 2023.

Beslutningen ble truffet med nødvendig flertall, jf. avstemmingsresultat inntatt som Vedlegg 2 til protokollen.

The resolution was passed with the required majority, cf. the result of the voting set out in Appendix 2 to the minutes.

8 FASTSETTELSE AV GODTGJØRELSE TIL STYRETS MEDLEMMER

8 DETERMINATION OF COMPENSATION PAYABLE TO THE MEMBERS OF THE BOARD OF DIRECTORS

I samsvar med valgkomiteens innstilling traff generalforsamlingen følgende vedtak:

In accordance with the nomination committee's proposal, the general meeting passed the following resolution:

Styrets leder skal motta NOK 300 000 for perioden fra den ordinære generalforsamlingen i 2022 frem til den ordinære generalforsamlingen i 2023. Alle andre styremedlemmer skal motta NOK 225 000 for den samme perioden. Selskapet kan kompensere styremedlemmene ytterligere dersom de påtar seg ekstraordinære arbeidsoppgaver for Selskapet utover styrevervet.

The chairperson of the board of directors shall receive NOK 300,000 for the period from the annual general meeting in 2022 until the annual general meeting in 2023. All other board members shall receive NOK 225,000 for the same period. The Company may compensate the board members for any extraordinary tasks performed for the Company beyond the directorship.

Honoraret skal utbetales umiddelbart etter den ordinære generalforsamlingen i 2023. Dersom et styremedlem ikke har sittet i styret i hele perioden skal honoraret nedjusteres forholdsvis (basert på antall dager i styret sammenlignet med hele perioden).

The remuneration shall be payable immediately after the annual general meeting in 2023. If a board member has not served for the entire period, the remuneration shall be pro rata adjusted downwards (based on the number of days served compared to the full period).

Som beskrevet i kapittel 6.16 punkt (ii) i Selskapets prospekt datert 8. februar 2022 bidro samtlige av Selskapets styremedlemmer i forbindelse med Selskapets oppkjøp av Biim Ultrasound AS. Styremedlemmenes bidrag med den tilknyttede selskapsgjennomgangen var av en slik art at valgkomiteen stiller seg bak vurderingen om at dette arbeidet går utover det som med rimelighet kan forventes å være dekket av styremedlemmenes ordinære arbeidsoppgaver som en del av styrearbeidet. Basert på mottatt honorarforslag i denne forbindelse innstiller derfor valgkomiteen at styremedlem Thomas Grünfeld får utbetalt NOK 204 000, styremedlem Kathrine Gamborg Andreassen får utbetalt NOK 150 000 og styremedlem Sanna Rydberg får utbetalt NOK 60 000 for dette arbeidet.

As described in section 6.16 item (ii) in the Company's prospectus dated 8 February 2022, all members of the Company's board of directors contributed with the Company's acquisition of Biim Ultrasound AS. The board members' contribution with the related due diligence review was of such nature that the nomination committee supports the assessment made that this work exceeds what could reasonably be expected to fall under the board members ordinary tasks as part of their directorships. On the basis of the received proposal for remuneration in connection therewith, the nomination committee thus recommends that board member Thomas Grünfeld receives payment of NOK 204,000, Kathrine Gamborg Andreassen receives payment of NOK 150,000 and board member Sanna Rydberg receives payment of NOK 60,000 for this work.

Videre fungerer også styremedlem Thomas B. Grünfeld som Selskapets Chief Medical Officer i henhold til en konsulentavtale. Det vises til kapittel 6.16 punkt (iii) i Selskapets prospekt datert 8. februar

Board member Thomas B. Grünfeld acts as the Company's Chief Medical Officer pursuant to a consultancy agreement. Reference is made to section 6.16 item (iii) in the Company's prospectus dated 8

2022 for mer informasjon om konsulentavtalen. Valgkomiteen innstiller på at konsulentavtalen med Thomas B. Grünfeld godkjennes av generalforsamlingen, herunder slik at medgått tid i henhold til avtalen kan betales i henhold til regning på løpende basis, og spesifikt at det samlede honoraret på NOK 1 187 000 for regnskapsåret 2021, godkjennes.

Beslutningen ble truffet med nødvendig flertall, jf. avstemningsresultat inntatt som Vedlegg 2 til protokollen.

9 FASTSETTELSE AV GODTGJØRELSE TIL REVISJONSUTVALGETS MEDLEMMER

I samsvar med valgkomiteens innstilling traff generalforsamlingen følgende vedtak:

Revisjonsutvalgets leder skal motta NOK 40 000 for perioden fra den ordinære generalforsamlingen i 2022 frem til den ordinære generalforsamlingen i 2023. Alle andre medlemmer av revisjonsutvalget skal motta NOK 30 000 for den samme perioden.

Honoraret skal utbetales umiddelbart etter den ordinære generalforsamlingen i 2023. Dersom et medlem av revisjonsutvalget ikke har sittet i revisjonsutvalget i hele perioden skal honoraret nedjusteres forholdsvis (basert på antall dager i revisjonsutvalget sammenlignet med hele perioden).

Beslutningen ble truffet med nødvendig flertall, jf. avstemningsresultat inntatt som Vedlegg 2 til protokollen.

10 FASTSETTELSE AV GODTGJØRELSE TIL VALGKOMITEENS MEDLEMMER

I samsvar med valgkomiteens innstilling traff generalforsamlingen følgende vedtak:

Valgkomiteens leder skal motta NOK 30 000 for perioden fra den ordinære generalforsamlingen i 2022 frem til den ordinære generalforsamlingen i 2023. Alle andre medlemmer av valgkomiteen skal motta NOK 20 000 for samme perioden.

Honoraret skal utbetales umiddelbart etter den ordinære generalforsamlingen i 2023. Dersom et medlem av valgkomiteen ikke har sittet i valgkomiteen i hele perioden skal honoraret nedjusteres forholdsvis (basert på antall dager i valgkomiteen sammenlignet med hele perioden).

Beslutningen ble truffet med nødvendig flertall, jf. avstemningsresultat inntatt som Vedlegg 2 til protokollen.

February 2022 for more information about the consultancy agreement. The nomination committee recommends that the consultancy agreement with Thomas B. Grünfeld is approved by the general meeting, including that accrued time spent pursuant to the agreement is paid in accordance with invoices on an ongoing basis, and specifically that the total remuneration of NOK 1,187,000 paid during the financial year 2021, is approved.

The resolution was passed with the required majority, cf. the result of the voting set out in Appendix 2 to the minutes.

9 DETERMINATION OF COMPENSATION TO THE MEMEBERS OF THE AUDIT COMMITTEE

In accordance with the nomination committee's proposal, the general meeting passed the following resolution:

The chairperson of the audit committee shall receive NOK 40,000 for the period from the annual general meeting in 2022 until the annual general meeting in 2023. All other members of the audit committee shall receive NOK 30,000 for the same period.

The remuneration shall be payable immediately after the annual general meeting in 2023. If a member of the audit committee has not served for the entire period, the remuneration shall be pro rata adjusted downwards (based on the number of days served compared to the full period).

The resolution was passed with the required majority, cf. the result of the voting set out in Appendix 2 to the minutes.

10 DETERMINATION OF COMPENSATION TO THE MEMBERS OF THE NOMINATION COMMITTEE

In accordance with the nomination committee's proposal, the general meeting passed the following resolution:

The chairperson of the nomination committee shall receive NOK 30,000 for the period from the annual general meeting in 2022 until the annual general meeting in 2023. All other members of the nomination committee shall receive NOK 20,000 for the same period.

The remuneration shall be payable immediately after the annual general meeting in 2023. If a member of the nomination committee has not served for the entire period, the remuneration shall be pro rata adjusted downwards (based on the number of days served compared to the full period).

The resolution was passed with the required majority, cf. the result of the voting set out in Appendix 2 to the minutes.

11 GODKJENNING AV GODTGJØRELSE TIL SELSKAPETS REVISOR FOR REGNSKAPSÅRET 2021

I samsvar med styrets forslag traff generalforsamlingen følgende vedtak:

Revisjonsgodtgjørelsen på NOK 966 000 (eks. mva) til KPMG AS for revisjon av Selskapets årsregnskap for regnskapsåret 2021 godkjennes.

Beslutningen ble truffet med nødvendig flertall, jf. avstemningsresultat inntatt som Vedlegg 2 til protokollen.

12 VALG AV NY REVISOR

I samsvar med styrets forslag traff generalforsamlingen følgende vedtak:

EY velges som revisor for Observe Medical ASA med virkning fra regnskapsåret 2022..

Beslutningen ble truffet med nødvendig flertall, jf. avstemningsresultat inntatt som Vedlegg 2 til protokollen.

13 STYRETS REDEGJØRELSE OM EIERSTYRING OG SELSKAPSLEDELSE

Møtelederen viste redegjørelsen om eierstyring og selskapsledelse inntatt på side side 27 i konsernets årsrapport for regnskapsåret 2021 for som er utarbeidet i henhold til regnskapsloven § 3-3b.

Generalforsamlingen tok redegjørelsen til etterretning.

14 STYRETS RETNINGSLINJER FOR FASTSETTELSE AV LØNN OG ANNEN GODTGJØRELSE TIL LEDENDE PERSONER

Møtelederen viste til styrets oppdaterte retningslinjer for fastsettelse av lønn og annen godtgjørelse til ledende personer i Selskapet som var gjort tilgjengelig på Selskapets hjemmeside samtidig med innkallingen. I samsvar med styrets forslag traff generalforsamlingen følgende vedtak:

Styrets forslag til retningslinjer for fastsettelse av lønn og annen godtgjørelse til ledende personer godkjennes.

Beslutningen ble truffet med nødvendig flertall, jf. avstemningsresultat inntatt som Vedlegg 2 til protokollen.

11 APPROVAL OF REMUNERATION TO THE COMPANY'S AUDITOR FOR THE FINANCIAL YEAR 2021

In accordance with the board of directors' proposal, the general meeting passed the following resolution:

The auditor's fee of NOK 966,000 (excl. VAT) to KPMG AS for the statutory audit of the Company's annual accounts for the financial year 2021 is approved.

The resolution was passed with the required majority, cf. the result of the voting set out in Appendix 2 to the minutes.

12 APPOINTMENT OF A NEW AUDITOR

In accordance with the board of directors' proposal, the general meeting passed the following resolution:

EY is elected as auditor for Observe Medical ASA effective from the fiscal year 2022.

The resolution was passed with the required majority, cf. the result of the voting set out in Appendix 2 to the minutes.

13 THE BOARD OF DIRECTORS' REPORT ON CORPORATE GOVERNANCE

The chair of the meeting referred to page 27 in the group's annual report for the financial year 2021 for the board of directors' report on corporate governance prepared in accordance with section 3-3b of the Norwegian Accounting Act.

The general meeting took note of the report.

14 THE BOARD OF DIRECTORS' GUIDELINES ON DETERMINATION OF SALARY AND OTHER REMUNERATION TO LEADING PERSONNEL

The chair of the meeting referred to the board of directors' updated guidelines for the determination of salary and other remuneration to the Company's leading personnel, which had been made available at the Company's website together with the notice. In accordance with the board of directors' proposal, the general meeting adopted the following resolution:

The board of directors' proposed guidelines on determination of salary and other remuneration to leading personnel are approved.

The resolution was passed with the required majority, cf. the result of the voting set out in Appendix 2 to the minutes.

15 RAPPORT OM LØNN OG ANNEN GODTGJØRELSE TIL LEDENDE PERSONER

I henhold til allmennaksjeloven § 6-16b hadde styret utarbeidet en rapport om lønn og annen godtgjørelse til ledende personer i Selskapet som var gjort tilgjengelig på Selskapets hjemmeside samtidig med innkallingen.

Generalforsamlingen avholdt en rådgivende avstemming over rapporten hvor generalforsamlingen besluttet å gi sin tilslutning til rapporten jf. avstemmingsresultatet inntatt som Vedlegg 2 til protokollen.

16 FULLMAKTER TIL STYRET TIL Å FORHØYE SELSKAPETS AKSJEKAPITAL

16.1 Fullmakt til styret til å forhøye aksjekapitalen i tilknytning til aksjeopsjoner og investeringsprogram

I samsvar med styrets forslag traff generalforsamlingen følgende vedtak:

- a) *I henhold til allmennaksjeloven § 10-14 gis styret fullmakt til å forhøye Selskapets aksjekapital med inntil NOK 750 000.*
- b) *Fullmakten gjelder frem til Selskapets ordinære generalforsamling i 2024, likevel ikke lenger enn til og med 2. juni 2024.*
- c) *Aksjeeiernes fortrinnsrett til de nye aksjene etter allmennaksjeloven § 10-4 kan fravikes.*
- d) *Fullmakten omfatter ikke kapitalforhøyelse mot innskudd i andre eiendeler enn penger eller rett til å pådra Selskapet særlige plikter mv., jf. allmennaksjeloven § 10-2.*
- e) *Fullmakten omfatter ikke kapitalforhøyelse ved fusjon etter allmennaksjeloven § 13-5.*

Beslutningen ble truffet med nødvendig flertall, jf. avstemmingsresultat inntatt som Vedlegg 2 til protokollen.

15 REPORT ON SALARY AND OTHER REMUNERATION TO LEADING PERSONNEL

In accordance with section 6-16b of the Norwegian Public Limited Liability Companies Act, the board of directors had prepared a report regarding remuneration of executive personnel, which had been made available at the Company's website together with the notice.

The report was considered by the general meeting by way of an advisory vote, whereupon the general meeting decided to endorse the report, cf. the result of the voting set out in Appendix 2 to these minutes.

16 AUTHORISATIONS TO THE BOARD OF DIRECTORS TO INCREASE THE COMPANY'S SHARE CAPITAL

16.1 Authorisation to the board of directors to increase the share capital in connection with share options and an investment program

In accordance with the board of directors' proposal, the general meeting passed the following resolution:

- a) *Pursuant to section 10-14 of the Norwegian Public Limited Liability Companies Act, the board of directors is granted an authorisation to increase the Company's share capital by up to NOK 750,000.*
- b) *The authorisation is valid until the Company's annual general meeting in 2024, but no longer than to and including 2 June 2024.*
- c) *The shareholders' pre-emptive right to the new shares in accordance with section 10-4 of the Norwegian Public Limited Liability Companies Act may be deviated from.*
- d) *The authorisation does not comprise share capital increases against contribution in kind or the right to incur specific obligations on behalf of the Company, cf. section 10-2 of the Norwegian Public Limited Liability Companies Act.*
- e) *The authorisation does not comprise share capital increase in connection with mergers pursuant to section 13-5 of the Norwegian Public Limited Liability Companies Act.*

The resolution was passed with the required majority, cf. the result of the voting set out in Appendix 2 to the minutes.

16.2 Fullmakt til styret til å forhøye aksjekapitalen for å finansiere videre vekst

I samsvar med styrets forslag traff generalforsamlingen følgende vedtak:

- a) I henhold til allmennaksjeloven § 10-14 gis styret fullmakt til å forhøye Selskapets aksjekapital med inntil NOK 2 781 566.
- b) Fullmakten gjelder frem til Selskapets ordinære generalforsamling i 2023, likevel ikke lenger enn til og med 30. juni 2023.
- c) Aksjeeiernes fortrinnsrett til de nye aksjene etter allmennaksjeloven § 10-4 kan fravikes.
- d) Fullmakten omfatter kapitalforhøyelse mot innskudd i andre eiendeler enn penger og rett til å pådra Selskapet særlige plikter mv., jf. allmennaksjeloven § 10-2.
- e) Fullmakten omfatter kapitalforhøyelse ved fusjon etter allmennaksjeloven § 13-5.

Beslutningen ble truffet med nødvendig flertall, jf. avstemmingsresultat inntatt som Vedlegg 2 til protokollen.

* * *

Mer forelå ikke til behandling og generalforsamlingen ble hevet.

* * *

DocuSigned by:

Terje Bakken

4319669DCF1D48D...

Terje Bakken

Møteleder / Chairperson

VEDLEGG:

1. Fortegnelsen over møtende aksjeeiere, inkludert antall aksjer og stemmer representert
2. Stemmeresultater

16.2 Authorisation to the board of directors to increase the share capital in order to finance further growth

In accordance with the board of directors' proposal, the general meeting passed the following resolution:

- a) Pursuant to section 10-14 of the Norwegian Public Limited Liability Companies Act, the board of directors is given an authorisation to increase the Company's share capital by up to NOK 2,781,566.
- b) The authorisation is valid until the Company's annual general meeting in 2023, but no longer than to and including 30 June 2023.
- c) The shareholders' pre-emptive right to the new shares in accordance with section 10-4 of the Norwegian Public Limited Liability Companies Act may be deviated from.
- d) The authorisation comprises share capital increases against contribution in kind and the right to incur specific obligations on behalf of the Company, cf. section 10-2 of the Norwegian Public Limited Liability Companies Act.
- e) The authorisation comprises share capital increases in connection with mergers pursuant to section 13-5 of the Norwegian Public Limited Liability Companies Act.

The resolution was passed with the required majority, cf. the result of the voting set out in Appendix 2 to the minutes.

* * *

There were no further matters to be discussed and the general meeting was adjourned.

* * *

DocuSigned by:

Per Arne Nygård

509240370330489...

Per Arne Nygård

Medundertegner / Co-signer

APPENDICES:

1. Record of attending shareholders, including the number of shares and votes represented
2. Voting results

3. juni 2022 / 3 June 2022



VEDLEGG 1 / APPENDIX 1

FORTEGNELSE OVER MØTENDE AKSJEIERE, INKLUDERT ANTALL AKSJER OG STEMME REPRESENTERT / RECORD OF ATTENDING SHAREHOLDERS, INCLUDING THE NUMBER OF SHARES

STEMMERESULTAT / VOTING RESULTS

Totalt representert

Observe Medical ASA

AGM

3 June 2022

Antall personer deltakende i møtet:	3
Totalt stemmeberettiget aksjer representert:	17 628 821
Totalt antall kontoer representert:	8
Totalt stemmeberettiget aksjer:	53 491 656
% Totalt representert stemmeberettiget:	32,96 %

	Sub Total:	3	0	17 628 821	
<u>Representert som</u>		<u>Deltakende i møtet</u>	<u>Ikke stemmende deltakere i møtet</u>	<u>Antall aksjer</u>	<u>Kontoer</u>
Shareholder (web)		1	0	2 072 086	1
Chair of the Board with Proxy		1	0	1 300	1
Chair of the Board with Instructions		1	0	15 555 435	6

Jostein Aspelien Engh
 DNB Bank ASA
 Issuer Services

Attendance Summary Report

Observe Medical ASA

AGM

3 June 2022

Registered Attendees:	3
Total Votes Represented:	17 628 821
Total Accounts Represented:	8
Total Voting Capital:	53 491 656
% Total Voting Capital Represented:	32,96 %

	Sub Total:	3	0	17 628 821	
<u>Capacity</u>		<u>Registered Attendees</u>	<u>Registered Non-Voting Attendees</u>	<u>Registered Votes</u>	<u>Accounts</u>
Shareholder (web)		1	0	2 072 086	1
Chair of the Board with Proxy		1	0	1 300	1
Chair of the Board with Instructions		1	0	15 555 435	6

Jostein Aspelien Engh
DNB Bank ASA
Issuer Services

OBSERVE MEDICAL ASA GENERAL MEETING 3 JUNE 2022

Som registreringsansvarlig for avstemmingen på generalforsamlingen for aksjonærene i selskapet avholdt den 3 juni 2022, BEKREFTES HERVED at resultatet av avstemmingen er korrekt angitt som følger:-

Totalt antall stemmeberettigede aksjer: 53 491 656

	STEMMER FOR / FOR	%	STEMMER MOT / AGAINST	%	STEMMER AVSTÅR / ABSTAIN	STEMMER TOTALT	% AV STEMME-BERETTIG KAPITAL AVGITT	IKKE AVGITT STEMME I MØTET
1	17 628 821	100,00	0	0,00	0	17 628 821	32,96 %	0
2	17 628 821	100,00	0	0,00	0	17 628 821	32,96 %	0
3	17 628 821	100,00	0	0,00	0	17 628 821	32,96 %	0
5	17 628 821	100,00	0	0,00	0	17 628 821	32,96 %	0
6	17 409 900	98,76	218 921	1,24	0	17 628 821	32,96 %	0
7	17 628 821	100,00	0	0,00	0	17 628 821	32,96 %	0
8	17 628 821	100,00	0	0,00	0	17 628 821	32,96 %	0
9	17 628 821	100,00	0	0,00	0	17 628 821	32,96 %	0
10	17 628 821	100,00	0	0,00	0	17 628 821	32,96 %	0
11	17 628 821	100,00	0	0,00	0	17 628 821	32,96 %	0
12	17 628 821	100,00	0	0,00	0	17 628 821	32,96 %	0
14	17 628 821	100,00	0	0,00	0	17 628 821	32,96 %	0
15	17 628 821	100,00	0	0,00	0	17 628 821	32,96 %	0
16,1	17 628 821	100,00	0	0,00	0	17 628 821	32,96 %	0
16,2	17 628 821	100,00	0	0,00	0	17 628 821	32,96 %	0

Jostein Aspelien Engh
 DNB Bank ASA
 Issuer Services

OBSERVE MEDICAL ASA GENERAL MEETING 3 JUNE 2022

As scrutineer appointed for the purpose of the Poll taken at the General Meeting of the Members of the Company held on 3 June 2022, I HEREBY CERTIFY that the result of the Poll is correctly set out as follows:-

Issued voting shares: 53 491 656

	VOTES FOR / FOR	%	VOTES MOT / AGAINST	%	VOTES AVSTÅR / ABSTAIN	VOTES TOTAL	% ISSUED VOTING SHARES VOTED	NO VOTES IN MEETING
1	17 628 821	100,00	0	0,00	0	17 628 821	32,96 %	0
2	17 628 821	100,00	0	0,00	0	17 628 821	32,96 %	0
3	17 628 821	100,00	0	0,00	0	17 628 821	32,96 %	0
5	17 628 821	100,00	0	0,00	0	17 628 821	32,96 %	0
6	17 409 900	98,76	218 921	1,24	0	17 628 821	32,96 %	0
7	17 628 821	100,00	0	0,00	0	17 628 821	32,96 %	0
8	17 628 821	100,00	0	0,00	0	17 628 821	32,96 %	0
9	17 628 821	100,00	0	0,00	0	17 628 821	32,96 %	0
10	17 628 821	100,00	0	0,00	0	17 628 821	32,96 %	0
11	17 628 821	100,00	0	0,00	0	17 628 821	32,96 %	0
12	17 628 821	100,00	0	0,00	0	17 628 821	32,96 %	0
14	17 628 821	100,00	0	0,00	0	17 628 821	32,96 %	0
15	17 628 821	100,00	0	0,00	0	17 628 821	32,96 %	0
16,1	17 628 821	100,00	0	0,00	0	17 628 821	32,96 %	0
16,2	17 628 821	100,00	0	0,00	0	17 628 821	32,96 %	0

Jostein Aspeliengh
DNB Bank ASA
Issuer Services

Certificate Of Completion

Envelope Id: 5D40E389E1514020BBF529AFB1ADBE17

Status: Completed

Subject: Please DocuSign: OMASA - Minutes of AGM.PDF, Tot rep Observe Med 030622 nor.pdf, Votes Observe ...

Source Envelope:

Document Pages: 13

Signatures: 2

Envelope Originator:

Certificate Pages: 5

Initials: 0

Stian Alexander Slaatta

AutoNav: Enabled

Ruseløkkveien 38

Envelopeld Stamping: Enabled

Oslo, Oslo 0251

Time Zone: (UTC+01:00) Amsterdam, Berlin, Bern, Rome, Stockholm, Vienna

sts@thommessen.no

IP Address: 81.175.32.90

Record Tracking

Status: Original

Holder: Stian Alexander Slaatta

Location: DocuSign

03 June 2022 | 10:12

sts@thommessen.no

Signer Events

Per Arne Nygård


perarne.nygard@observemedical.com

CFO

Observe Medical

Security Level: Email, Account Authentication
(None)**Signature**

DocuSigned by:

Per Arne Nygård
509249379330489...**Timestamp**

Sent: 03 June 2022 | 10:24

Viewed: 03 June 2022 | 10:25

Signed: 03 June 2022 | 10:25

Signature Adoption: Drawn on Device

Signed by link sent to

perarne.nygard@observemedical.com

Using IP Address: 46.46.203.233

Signed using mobile

Electronic Record and Signature Disclosure:

Accepted: 07 February 2022 | 19:17

ID: 516c45da-672a-477c-ac6e-28a4496f3670

Terje Bakken

tb@reitenco.no

Chairman

Security Level: Email, Account Authentication
(None)

DocuSigned by:

Terje Bakken
4319669DCF1D48D...

Sent: 03 June 2022 | 10:24

Viewed: 03 June 2022 | 10:28

Signed: 03 June 2022 | 10:29

Signature Adoption: Pre-selected Style

Signed by link sent to tb@reitenco.no

Using IP Address: 188.95.247.249

Electronic Record and Signature Disclosure:

Accepted: 03 June 2022 | 10:28

ID: b38d6790-3b54-49a4-b450-423f9cb93e0b

In Person Signer Events**Signature****Timestamp****Editor Delivery Events****Status****Timestamp****Agent Delivery Events****Status****Timestamp****Intermediary Delivery Events****Status****Timestamp****Certified Delivery Events****Status****Timestamp****Carbon Copy Events****Status****Timestamp****Witness Events****Signature****Timestamp****Notary Events****Signature****Timestamp**

Envelope Summary Events	Status	Timestamps
Envelope Sent	Hashed/Encrypted	03 June 2022 10:24
Certified Delivered	Security Checked	03 June 2022 10:28
Signing Complete	Security Checked	03 June 2022 10:29
Completed	Security Checked	03 June 2022 10:29

Payment Events	Status	Timestamps
-----------------------	---------------	-------------------

Electronic Record and Signature Disclosure

ELECTRONIC RECORD AND SIGNATURE DISCLOSURE

From time to time, Advokatfirmaet Thommessen AS (we, us or Company) may be required by law to provide to you certain written notices or disclosures. Described below are the terms and conditions for providing to you such notices and disclosures electronically through the DocuSign system. Please read the information below carefully and thoroughly, and if you can access this information electronically to your satisfaction and agree to this Electronic Record and Signature Disclosure (ERSD), please confirm your agreement by selecting the check-box next to 'I agree to use electronic records and signatures' before clicking 'CONTINUE' within the DocuSign system.

Getting paper copies

At any time, you may request from us a paper copy of any record provided or made available electronically to you by us. You will have the ability to download and print documents we send to you through the DocuSign system during and immediately after the signing session and, if you elect to create a DocuSign account, you may access the documents for a limited period of time (usually 30 days) after such documents are first sent to you. After such time, if you wish for us to send you paper copies of any such documents from our office to you, you will be charged a \$0.00 per-page fee. You may request delivery of such paper copies from us by following the procedure described below.

Withdrawing your consent

If you decide to receive notices and disclosures from us electronically, you may at any time change your mind and tell us that thereafter you want to receive required notices and disclosures only in paper format. How you must inform us of your decision to receive future notices and disclosure in paper format and withdraw your consent to receive notices and disclosures electronically is described below.

Consequences of changing your mind

If you elect to receive required notices and disclosures only in paper format, it will slow the speed at which we can complete certain steps in transactions with you and delivering services to you because we will need first to send the required notices or disclosures to you in paper format, and then wait until we receive back from you your acknowledgment of your receipt of such paper notices or disclosures. Further, you will no longer be able to use the DocuSign system to receive required notices and consents electronically from us or to sign electronically documents from us.

All notices and disclosures will be sent to you electronically

Unless you tell us otherwise in accordance with the procedures described herein, we will provide electronically to you through the DocuSign system all required notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you during the course of our relationship with you. To reduce the chance of you inadvertently not receiving any notice or disclosure, we prefer to provide all of the required notices and disclosures to you by the same method and to the same address that you have given us. Thus, you can receive all the disclosures and notices electronically or in paper format through the paper mail delivery system. If you do not agree with this process, please let us know as described below. Please also see the paragraph immediately above that describes the consequences of your electing not to receive delivery of the notices and disclosures electronically from us.

How to contact Advokatfirmaet Thommessen AS:

You may contact us to let us know of your changes as to how we may contact you electronically, to request paper copies of certain information from us, and to withdraw your prior consent to receive notices and disclosures electronically as follows:

To contact us by email send messages to: saa@thommessen.no

To advise Advokatfirmaet Thommessen AS of your new email address

To let us know of a change in your email address where we should send notices and disclosures electronically to you, you must send an email message to us at saa@thommessen.no and in the body of such request you must state: your previous email address, your new email address. We do not require any other information from you to change your email address.

If you created a DocuSign account, you may update it with your new email address through your account preferences.

To request paper copies from Advokatfirmaet Thommessen AS

To request delivery from us of paper copies of the notices and disclosures previously provided by us to you electronically, you must send us an email to saa@thommessen.no and in the body of such request you must state your email address, full name, mailing address, and telephone number. We will bill you for any fees at that time, if any.

To withdraw your consent with Advokatfirmaet Thommessen AS

To inform us that you no longer wish to receive future notices and disclosures in electronic format you may:

i. decline to sign a document from within your signing session, and on the subsequent page, select the check-box indicating you wish to withdraw your consent, or you may;

ii. send us an email to saa@thommessen.no and in the body of such request you must state your email, full name, mailing address, and telephone number. We do not need any other information from you to withdraw consent.. The consequences of your withdrawing consent for online documents will be that transactions may take a longer time to process..

Required hardware and software

The minimum system requirements for using the DocuSign system may change over time. The current system requirements are found here: <https://support.docusign.com/guides/signer-guide-signing-system-requirements>.

Acknowledging your access and consent to receive and sign documents electronically

To confirm to us that you can access this information electronically, which will be similar to other electronic notices and disclosures that we will provide to you, please confirm that you have read this ERSD, and (i) that you are able to print on paper or electronically save this ERSD for your future reference and access; or (ii) that you are able to email this ERSD to an email address where you will be able to print on paper or save it for your future reference and access. Further, if you consent to receiving notices and disclosures exclusively in electronic format as described herein, then select the check-box next to ‘I agree to use electronic records and signatures’ before clicking ‘CONTINUE’ within the DocuSign system.

By selecting the check-box next to ‘I agree to use electronic records and signatures’, you confirm that:

- You can access and read this Electronic Record and Signature Disclosure; and
- You can print on paper this Electronic Record and Signature Disclosure, or save or send this Electronic Record and Disclosure to a location where you can print it, for future reference and access; and
- Until or unless you notify Advokatfirmaet Thommessen AS as described above, you consent to receive exclusively through electronic means all notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you by Advokatfirmaet Thommessen AS during the course of your relationship with Advokatfirmaet Thommessen AS.